The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
